12 September 2025 in Journal of Community Hospital Internal Medicine Perspectives
Bi-atrial thrombi with bilateral pulmonary embolism (PE) through a patent foramen ovale (PFO) is rare and life-threatening, requiring urgent management due to embolization risk. We present a 53-year-old female with left lower extremity extensive deep vein thrombosis (DVT), bilateral PE, and bi-atrial thrombi straddling a PFO. She underwent thrombectomy, PFO closure, and pulmonary embolectomy but later experienced recurrent DVT and PE. Anticoagulation was limited due to bleeding risk given a recent neurosurgery. Literature lacks clear guidelines for managing such cases necessitating individualized treatment. This case highlights the complexity of bi-atrial thrombi with PFO and the need for further research to optimize management strategies.
8 August 2025 in European Heart Journal - Case Reports
Background: Transcatheter aortic valve replacement (TAVR) thrombosis is a known complication, but its association with vascular endothelial growth factor inhibitors has not been previously reported. Case Summary: A 69-year-old male with previous TAVR developed new-onset prosthetic valve dysfunction after receiving bevacizumab for age-related macular degeneration. Echocardiography revealed moderate aortic stenosis with significantly elevated gradients compared to baseline. Following discontinuation of bevacizumab and initiation of systemic anticoagulation, valve function normalized at three-month follow-up. Discussion: This first reported case of TAVR thrombosis potentially linked to bevacizumab therapy demonstrates a temporal relationship between drug administration and valve dysfunction, with subsequent resolution upon drug discontinuation and anticoagulation. Conclusion: Clinicians should be aware of potential thrombotic complications when prescribing bevacizumab to patients with bioprosthetic valves and maintain regular echocardiographic surveillance. Prompt anticoagulation and medication adjustment may reverse valve dysfunction. Further studies are needed to determine a causal relationship between TAVR thrombosis and VEGF inhibitors.